Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 1
2018 1
2019 1
2020 4
2021 4
2022 5
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: chien ks. J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. J Clin Oncol. 2024. PMID: 38277619 Clinical Trial.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: chien ks. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Urrutia S, et al. Among authors: chien ks. Am J Hematol. 2023 Oct;98(10):E281-E284. doi: 10.1002/ajh.27043. Epub 2023 Jul 29. Am J Hematol. 2023. PMID: 37515433
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. Bataller A, et al. Among authors: chien ks. Leuk Res. 2023 Apr;127:107044. doi: 10.1016/j.leukres.2023.107044. Epub 2023 Feb 15. Leuk Res. 2023. PMID: 36801700 No abstract available.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Among authors: chien ks. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. Desikan SP, et al. Among authors: chien ks. Acta Haematol. 2022;145(5):529-536. doi: 10.1159/000525566. Epub 2022 Jun 17. Acta Haematol. 2022. PMID: 35717939 Free article. Clinical Trial.
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.
Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Zuo Z, et al. Among authors: chien ks. Biology (Basel). 2022 Dec 21;12(1):13. doi: 10.3390/biology12010013. Biology (Basel). 2022. PMID: 36671709 Free PMC article.
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. Wei Y, et al. Among authors: chien ks. Leuk Lymphoma. 2022 Dec;63(13):3154-3164. doi: 10.1080/10428194.2022.2116932. Epub 2022 Sep 5. Leuk Lymphoma. 2022. PMID: 36059252 Free PMC article.
27 results